Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The creation of a percutaneous arteriovenous fistula (pAVF) for hemodialysis (HD) using endovascular devices is a viable alternative to surgical AVFs (sAVFs). In Spain, experience has grown with the WavelinQ system (WQ), enabling anastomosis between radial or ulnar artery and vein at the proximal forearm. More recently, the Ellipsys® system (ES) has been used to connect the proximal radial artery to the perforating vein.
We included 19 patients (13 men, 6 women; mean age 60.9 years) undergoing pAVF creation between Nov 2019 and Nov 2024: 8 with advanced CKD, 7 on HD, 3 kidney transplant recipients, and 1 hospitalized. Eighteen pAVFs were created with WQ and one with ES. Most patients had predictors of sAVF non-functionality (sAVF-NF): diabetes (68%), overweight (BMI >25, 58%) or obesity (BMI >30, 37%), peripheral vascular disease (37%), central vein thrombosis (26%), and previous sAVF-NF (74%).
Fistulas included 15 radio-radial, 2 ulnar-ulnar, 1 ulnar-brachial, and 1 radio-perforating; 8 were right-sided, 11 left. Technical success: 18/19 (94.7%), with one failure due to arterial calcification. Maturation occurred in 16/19 (84%), with early thrombosis in one and lack of maturation in another. Definitive failure in 5/19 (25%), including two late thromboses. Complications: 3 hematomas and 1 vasospasm. Intra-procedure interventions in 11/18 patients (1 angioplasty, 4 embolizations, 6 both). Endovascular reinterventions required in 63%: 11 for maturation and 12 for maintenance.Main complications: thrombosis and delayed maturation.Mean maturation time: 90±105 days (range 11–432).Mean usability: 281±204 days (range 46–652).Primary patency: 293±263 days (range 30–855).Secondary patency: 707±418 days (range 209–1835).Final patency at follow-up: 74% (14/19).
In this high-risk cohort, pAVF creation showed high technical success (95%) and 74% follow-up patency, despite frequent endovascular reinterventions. Compared to existing data, maturation and usability times were longer, likely due to case complexity. WavelinQ-based pAVFs are a promising option in patients with suboptimal access conditions. Better patient selection and growing operator expertise may improve outcomes. No major complications occurred. Further optimization and standardization may enhance results. Prospective, multicenter studies are needed to refine criteria, define best practices, and assess cost-effectiveness versus surgical AVFs.
